Tirzepatide ���子背景与靶点 — Field Notes

By Editorial Desk · published 2025-07-23 · last reviewed 2025-08-19 · Topic

Everything below concerns 脂肪酸侧链. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。

Background and Molecular Development

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.

Tirzepatide at a glance

Background and Dual Receptor Pharmacology

Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Related pages on this site

• Portable workbook
• Automated casebook
• Modular index
• Modular summary
• Modern workbook
• Connected reference
• Proven index
• Tracked update

Molecular Basis and Receptor Pharmacology

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

Dual Incretin Receptor Agonism

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Background And Receptor Pharmacology

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Further detail

where Ni is the number of molecules of molecular mass Mi. The mass average molecular mass can be determined by static light scattering, small angle neutron scattering, X-ray scattering, and sedimentation velocity. The ratio of the mass average to the number average is called the dispersity or the polydispersity index. The mass-average molecular mass, Mw, is also related to the fractional monomer conversion, p, in step-growth polymerization (for the simplest case of linear polymers formed from two monomers in equimolar quantities) as per Carothers' equation:

His plan fails and he rejoins Freeman's group. Freeman then finds Bubby stuck in his old test tube, who had also been betrayed by the military, along with Benry. Freeman reluctantly allows them to rejoin the group. The science team proceed to Black Mesa's Mixology Department, headed by Darnold (Logmore), who gives Freeman a potion that causes his missing arm to regrow into a machine gun. The team fight their way to the Lambda Complex, where they teleport to Xen. In Xen, they find Benry has grown into a giant and begins floating around the others, taunting them. Benry is revealed to be the source of the resonance cascade, transforming into a monstrous alien form and attacking the rest of the science team, who work together to eventually defeat him, by time traveling to the beginning of the game to retrieve their passports. After defeating Benry, Freeman is captured by the G-Man (Spaghoner), who thanks him for taking down Benry and invites him to the birthday party of Tommy, revealed to be the G-Man's adopted son. In the credits sequence, the science team and the G-Man celebrate Tommy's birthday at a Chuck E. Cheese, much to Freeman's despair. In a post-credits scene, Dr. Coomer calls Freeman and congratulates him for beating the game, thanking him for taking the science team with him on his adventure.

=== Peptide === Ghrelin (Lenomorelin, GHRL) GHRP-1 GHRP-2 (Pralmorelin; GHRP Kaken 100; GHRP-2; KP-102, GPA-748, WAY-GPA-748) GHRP-3 GHRP-4 GHRP-5 GHRP-6 (SKF-110679) Alexamorelin Examorelin (hexarelin; EP-23905, MF-6003) Ipamorelin (NNC 26-0161) Relamorelin (RM-131, BIM-28131, BIM-28163) Tabimorelin (NN-703)

Sources: en.wikipedia.org

Supporting material

=== United States === In the US, there can be stigma that hinders people with sickle cell disease from receiving necessary care; one element of this is attributed to racism as the majority of people with sickle cell disease are black. Due to this, in 1970, the Black Panther Party (also known as the Black Panther Party for Self Defense) opened dozens of free clinics across the U.S. where free Sickle Cell Disease tests were offered. Over the course of the 1970s, thousands of people, largely African-Americans, received testing at one of these clinics. In September 2017, the US Social Security Administration issued a policy interpretation ruling providing background information on sickle cell disease and a description of how Social Security evaluates the disease during its adjudication process for disability claims.

Rosett (1953), dean of the University of Chicago Booth School of Business, Arts and Sciences at Washington University in St. Louis, and chairman of National Bureau of Economic Research Robert L. Friedheim (1955), former director of the USC School of International Relations Calvin B. T. Lee (1955), former chancellor of University of Maryland, Baltimore County and acting president of Boston University Robert E. Paaswell (1956), civil engineer, former interim president of City College of New York and CEO of Chicago Transit Authority Kenneth Gros Louis (1959), chancellor of Indiana University system Richard A. Merrill (1959), 7th dean of the University of Virginia School of Law Stephen Joel Trachtenberg (1959), president of the University of Hartford and of George Washington University David C. Levy (1960), dean of the Parsons School of Design and president of the Corcoran Gallery of Art Steven M. Cahn (1966), provost and acting president of Graduate Center of the City University of New York Dimitri B. Papadimitriou (1970), executive vice president and provost of Bard College David Rubin (1970), professor of communications and dean of S. I. Newhouse School of Public Communications Alan Cooper (1971), provost of Jewish Theological Seminary of America, former member of Sha Na Na William Germano (1972), dean of the faculty of humanities and social sciences at Cooper Union, former editor-in-chief of Columbia University Press Saul Levmore (1973), commercial law scholar, former dean of the University of Chicago Law School Ronald Mason Jr.

In the UK no formal qualification or certification is required prior to becoming a phlebotomist as training is usually provided on the job. The NHS offers training with formal certification upon completion.

Sources: en.wikipedia.org

Supporting material

=== Degradation of collagen === UV exposure would also lead to the activation of receptors for epidermal growth factor, IL-1, and TNF-α in keratinocytes and fibroblasts, which then activate signaling kinases throughout the skin via an unknown mechanism. The nuclear transcription factor activator protein, AP-1, which controls the transcription of matrix metalloproteinases (MMP), is expressed and activated. MMP-1 is a major metalloproteinase for collagen degradation. This entire process is aided by the presence of reactive oxygen species that inhibit protein-tyrosine phosphatases via oxidation, thereby resulting in the up-regulation of the above-mentioned receptors. Another transcription factor, NF-κB, which is also activated by UV light, increases the expression of MMP-9. The up-regulation of MMP can occur even after minimal exposure to UV; hence, exposure to UV radiation that is inadequate to cause sunburn can facilitate the degradation of skin collagen and, presumably, lead to eventual photoaging. Thus, collagen production is reduced in photoaged skin due to the process of constant degradation of collagen mediated by MMPs. In addition, the presence of damaged collagen would also downregulate the synthesis of new collagen. The impaired spreading and attachment of fibroblasts onto degraded collagen could be one of the contributing factors to the inhibition of collagen synthesis.

== Development == The game was originally created and released by Daniel Fearon. At the time, Fearon was one of the maintainers of the Half-Life fan website Atomic Half-Life, created in anticipation of the game's release. Fearon was sent a copy of Half-Life by Valve prior to its official release, and while playing it, he toyed with the game's code, figuring out how to spawn enemy creatures in multiplayer maps. Fearon's work had initially been done before Valve released the software development kit for Half-Life, requiring him to craft the modification atop the existing Half-Life distribution and to work with multiplayer over slower internet connections, such as phone-line modems. Fearon initially developed a single map that could be played cooperatively, and later a second version with two maps. The first public version of Sven Co-op was released on January 19, 1999, about 3 months after the release of Half-Life. He used the name Sven Co-op to reflect his online handle, "Sven Viking". Contrary to the common belief that Sven Co-op was developed to play through Half-Life cooperatively, Fearon had wanted to create a means for players to engage in cooperative experiences together, often just spawning in large number of enemies for them to dispatch together on a single map. This drew a number of amateur level developers to craft mission-based maps for the mod, where players would be required to go to different areas on the map based on success or failure of a given objective.

Outline of the 2026 Iran war Censorship during the 2026 Iran war Impact of the 2026 Iran war on the 2026 FIFA World Cup Misinformation during the 2026 Iran war Operation Project Freedom Alleged Iranian attempts to assassinate Donald Trump Economic impact of the 2026 Iran war Letter from the IRGC to the American people Related events American expansionism under Donald Trump 1979 oil crisis March–May 2025 United States attacks in Yemen 2026 United States intervention in Venezuela Iranian economic crisis List of wars involving Iran

Sources: en.wikipedia.org

Frequently asked questions